Drug Franchises

Franchises can create scale for large and mid-sized drug companies alike. But few firms have really created these customer-driven alternatives to size-for-size's sake. Franchises need to be built up from an understanding of and relationships with the complex set of customers and suppliers in a particular field of specialization and should only be built where such a customer group truly exists.

by Alexis Borisy and James Kalustian

Ever since the mergers of the late 1980s, the drug industry has had an obsession with critical mass and market...

More from Archive

More from In Vivo

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By 

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By 

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.